CTOL Digital Solutions: Pioneering Swiss Intelligence and Digital Tech Services (I’m sorry I can’t respond to all messages right now as we’re focused on our main projects. Thank you so much for understanding!)
Atossa Therapeutics Modifies Breast Cancer Trial with Increased (Z)-endoxifen Dose Atossa Therapeutics has adjusted its ongoing clinical trial by augmenting the dose of (Z)-endoxifen and blending it with Eli Lilly's abemaciclib to target ER+/HER2- breast cancer. This alteration is based on favorable results from the Phase II EVANGELINE study, demonstrating a significant reduction in the cellular proliferation marker Ki-67 and the size of tumors. The updated trial will encompass about 80 participants across two cohorts, covering both pre- and post-menopausal women. Notably, premenopausal women in the second cohort will also undergo ovarian function suppression to facilitate direct outcome comparisons. Atossa's CEO, Steven Quay, expressed enthusiasm concerning the protocol update and the backing from Eli Lilly, highlighting the positive safety profile and optimal drug concentrations achieved with the increased (Z)-endoxifen dosage. # Thank you Elena Barbosa for your submission!
